In a Twitter message dated Dec. 4, the company said it is suspending its US operations for the time being "due to an unexpected adverse financing situation."
Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.
The approval of its Omics Core assay for tumor-normal mutational profiling opens the door for payor reimbursement, which is key to reaching profitability, NantHealth said.
Analyzing patient exome sequence data, investigators identified germline variants with apparent ties to estrogen receptor-positive breast cancer recurrence.
Exome sequences from dozens of cervical cancer tumor or primary cell line samples revealed recurrent alterations affecting ERBB2/HER2 and PIK3CA pathways.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.
